Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)

NCT06500793

Status	RECRUITING
Phase	Phase 1
Sponsor	Ensysce Biosciences
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (7)

- Must be able to understand a written informed consent, which must be obtained prior to initiation of study procedures.
- Must be willing and able to comply with all study requirements.
- Aged 18 to 55 years, inclusive, at time of signing informed consent.
- Must agree to use an adequate method of contraception (as defined in Section 9.4).
- Healthy males or non pregnant, non lactating healthy females.

... and 2 more (see full listing online)

Exclusion (32)

- Serious adverse reaction or serious hypersensitivity to any drug or formulation excipients.
- Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active.
- Significant serious skin disease, including rash, food allergy, eczema, psoriasis, or urticaria.
- History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or GI disease (Part 1 only: except cholecystectomy), gastrointestinal surgery (e.g. gastric bypass, gastric banding, colectomy), or neurological or psychiatric disorder, as judged by the investigator.
- Subjects with a history of seizures.

... and 27 more (see full listing online)

Locations (1 total)

Quotient Sciences, Miami, Florida, United States